Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain. Methods and Results This is an exploratory analysis of the TICH‐2 (Tranexamic Acid in Intracerebral Hemorrhage‐2) double‐blind, randomized, placebo‐controlled trial, which studied the efficacy of tranexamic acid in patients with spontaneous ICH within 8 hours of onset. Multivariable logistic regression and ordinal regression were performed to explore the relationship between pre‐ICH antiplatelet therapy, and 24‐hour hematoma expansion and day 90 modified Rankin Scale score, as well as the effect of tranexamic acid. Of 2325 patients, 611 (26.3%) had pre‐ICH antiplatelet therapy. They were older (mean age, 75.7 versus 66.5 years), more likely to have ischemic heart disease (25.4% versus 2.7%), ischemic stroke (36.2% versus 6.3%), intraventricular hemorrhage (40.2% versus 27.5%), and larger baseline hematoma volume (mean, 28.1 versus 22.6 mL) than the no‐antiplatelet group. Pre‐ICH antiplatelet therapy was associated with a significantly increased risk of hematoma expansion (adjusted odds ratio [OR], 1.28; 95% CI, 1.01–1.63), a shift toward unfavorable outcome in modified Rankin Scale (adjusted common OR, 1.58; 95% CI, 1.32–1.91) and a higher risk of death at day 90 (adjusted OR, 1.63; 95% CI, 1.25–2.11). Tranexamic acid reduced the risk of hematoma expansion in the overall patients with ICH (adjusted OR, 0.76; 95% CI, 0.62–0.93) and antiplatelet subgroup (adjusted OR, 0.61; 95% CI, 0.41–0.91) with no significant interaction between pre‐ICH antiplatelet therapy and tranexamic acid (P interaction=0.248). Conclusions Antiplatelet therapy is independently associated with hematoma expansion and unfavorable functional outcome. Tranexamic acid reduced hematoma expansion regardless of prior antiplatelet therapy use. Registration URL: https://www.isrctn.com; Unique identifier: ISRCTN93732214.

[1]  R. Al‐Shahi Salman,et al.  Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial , 2020, BMJ Open.

[2]  P. Bath,et al.  Elevated plasminogen activators are associated with hematoma progression in spontaneous intracerebral hemorrhage , 2020, Brain Hemorrhages.

[3]  L. Cala,et al.  Noncontrast Computed Tomography Signs as Predictors of Hematoma Expansion, Clinical Outcome, and Response to Tranexamic Acid in Acute Intracerebral Hemorrhage , 2019, Stroke.

[4]  S. Pocock,et al.  Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. , 2019, Health technology assessment.

[5]  I. Roberts,et al.  No effect of tranexamic acid on platelet function and thrombin generation (ETAPlaT) in postpartum haemorrhage: a randomised placebo-controlled trial , 2019, Wellcome open research.

[6]  T. Struffert,et al.  Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation–Associated Intracerebral Hemorrhage , 2018, Stroke.

[7]  Y. Fujii,et al.  Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data , 2018 .

[8]  S. Pocock,et al.  Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial , 2018, The Lancet.

[9]  C. Nolte,et al.  Prior antiplatelet therapy is not associated with larger hematoma volume or hematoma growth in intracerebral hemorrhage , 2018, Neurological Sciences.

[10]  C. Gandhi,et al.  Clinical and Radiographic Predictors of Intracerebral Hemorrhage Outcome , 2018, Interventional Neurology.

[11]  Daisuke Shimbo,et al.  Impact of Antiplatelets and Anticoagulants on the Prognosis of Intracerebral Hemorrhage. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[12]  Anders Larsson,et al.  Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet Neurology.

[13]  A. Meretoja,et al.  Treatment of intracerebral haemorrhage with tranexamic acid – A review of current evidence and ongoing trials , 2017, European stroke journal.

[14]  E. Cuadrado Godia,et al.  Antithrombotic pretreatment increases very-early mortality in primary intracerebral hemorrhage , 2017, Neurology.

[15]  R. Delgado-Mederos,et al.  Does prior antiplatelet therapy influence hematoma volume and hematoma growth following intracerebral hemorrhage? Results from a prospective study and a meta‐analysis , 2017, European journal of neurology.

[16]  Rustam Al-Shahi Salman,et al.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial , 2016, The Lancet.

[17]  S. Pocock,et al.  Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial , 2016, International journal of stroke : official journal of the International Stroke Society.

[18]  M. Sasaki,et al.  Do the antithrombotic therapy at the time of intracerebral hemorrhage influence clinical outcome? analysis between the difference of antiplatelet and anticoagulant agents and clinical course. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[19]  E. Grove,et al.  Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure , 2013, PloS one.

[20]  E. Arsava,et al.  Previous antiplatelet use is associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[21]  Mu‐Shun Huang,et al.  Emergency department neurologic deterioration in patients with spontaneous intracerebral hemorrhage: incidence, predictors, and prognostic significance. , 2012, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[22]  A. Naidech,et al.  Prior antiplatelet therapy and outcome following intracerebral hemorrhage: A systematic review , 2011, Neurology.

[23]  A. Moritz,et al.  Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy , 2011, European journal of anaesthesiology.

[24]  M. Alberts,et al.  REDUCED PLATELET ACTIVITY IS ASSOCIATED WITH MORE INTRAVENTRICULAR HEMORRHAGE , 2009, Neurosurgery.

[25]  M. Alberts,et al.  Reduced Platelet Activity Is Associated With Early Clot Growth and Worse 3-Month Outcome After Intracerebral Hemorrhage , 2009, Stroke.

[26]  S. Kasner,et al.  Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH , 2009, Neurology.

[27]  K. Nagata,et al.  Antithrombotic Therapy Influences Location, Enlargement, and Mortality from Intracerebral Hemorrhage , 2008, Cerebrovascular Diseases.

[28]  C. Anderson,et al.  Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial , 2008, The Lancet Neurology.

[29]  K. Mann,et al.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. , 2007, Blood.

[30]  T. Neumann-Haefelin,et al.  Pretreatment With Antiplatelet Agents Is Not Independently Associated With Unfavorable Outcome in Intracerebral Hemorrhage , 2006, Stroke.

[31]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[32]  E. Savolainen,et al.  Regular Aspirin-Use Preceding the Onset of Primary Intracerebral Hemorrhage is an Independent Predictor for Death , 2006, Stroke.

[33]  J. Horrow,et al.  Effect of tranexamic acid on platelet ADP during extracorporeal circulation , 1991, American journal of hematology.